Elucid Raises $55 Million in Oversubscribed Series D Financing
Funding will accelerate commercialization of Elucid’s AI-powered cardiovascular imaging platform and expand strategic partnerships with leading medical technology companies BOSTON — Sept. 2, 2026 — Elucid, a medical technology company using AI-powered, clinically validated software to advance precision diagnosis and treatment of cardiovascular disease, today announced the raise of $55 million in an oversubscribed Series […]
Elucid Announces First Patient Enrollment in AI-PREDICT, a Landmark International Study to Define Lesion-Level Cardiovascular Risk
Elucid, an innovator in AI-powered coronary CT angiography (CCTA) analysis, today announced first patient enrollment in AI-PREDICT, a retrospective, international, multicenter study designed to establish a new lesion-centric paradigm for cardiovascular risk stratification.
Elucid to Showcase CCTA Vision at SCCT 2026, Defining the Future of Personalized Cardiovascular Care
Elucid, an innovator in AI-powered coronary CT angiography (CCTA) analysis, today announced its largest and most comprehensive presence to date at the Society of Cardiovascular Computed Tomography Annual Scientific Meeting (SCCT 2026), taking place July 9 – 12, 2026, at the Gaylord Pacific Resort & Convention Center in Chula Vista, Calif.
Elucid’s Plaque-IQ™ Named “Best New Cardiology Technology Solution” in 2026 MedTech Breakthrough Awards Program
Elucid today announced that its Plaque-IQ arterial plaque analysis software has been selected as winner of the “Best New Cardiology Technology Solution” award in the 10th annual MedTech Breakthrough Awards.
Elucid’s PlaqueIQ Image Analysis Software Included in EviCore Coverage Guidelines
Elucid, an AI medical technology company focused on providing physicians with a more precise view of atherosclerosis to drive patient-specific therapeutic decisions, today announced that EviCore, a radiology benefit manager, has updated its cardiac imaging guidelines to include coverage of coronary computed tomography angiography (CTA) plaque quantification (see pages 82-84), effective October 1, 2025.
Elucid Announces CCTA Reimbursement to be Doubled with CMS Rule
Elucid has announced a final rule from US Centers for Medicare & Medicaid Services (CMS) that will significantly increase the reimbursement for cardiac computed tomography angiography (CCTA).
Elucid Receives U.S. 510(k) Clearance of PlaqueIQ™ Image Analysis Software to Aid Cardiovascular Disease Assessment
Elucid has announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its PlaqueIQ™ imaging analysis software to help physicians diagnose cardiovascular disease (CVD).
Elucid Names Kelly Huang as CEO
Elucid, a pioneering AI medical technology company providing physicians with imaging analysis software based on ground truth histology to support treatment of cardiovascular disease, has named Kelly Huang, PhD, as president and chief executive officer (CEO).
Elucid Commences International PRE-VUE CCT Registry Study
Elucid has initiated site recruitment for its Plaque as a Risk Factor for Evaluation of Vascular Events (PRE-VUE) CT Registry Study.
Elucid Moves into New Headquarters in Preparation for Commercial Launch
Elucid today announced it has moved its headquarters to 399 Boylston Street in the heart of Boston’s Back Bay neighborhood.